Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Naive Subjects With Chronic HCV Infection

Trial Profile

A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Naive Subjects With Chronic HCV Infection

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sofosbuvir/velpatasvir/voxilaprevir (Primary) ; Sofosbuvir/velpatasvir
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms POLARIS-2
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 01 Oct 2018 Results of a pooled analysis assessing patients reported outcomes from 11 studies, published in the Value in Health.
    • 05 Dec 2017 Results of resistance analysis in HCV infected patients Genotype 1-6 from phase III studies (ASTRAL-1, ASTRAL-2, ASTRAL-3, ASTRAL-5 and POLARIS-2, POLARIS-3; n=1778) published in the Journal of Hepatology
    • 27 Nov 2017 Results assessing patient-reported outcomes from POLARIS 2 and 3 (n=1160) published in the Alimentary Pharmacology and Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top